June 4 - June 8, 2021 VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on 4-8 June 2021. May 11, 2021 at 8:30 AM EDT VBL Therapeutics Q1 2021 Financial Results conference call Webcast April 6, 2021 from 10:00 AM to 12:00 PM EDT Virtual R&D Day March 25, 2021 at 8:30 AM EDT VBL Therapeutics Fourth Quarter 2020 and Full Year Financial Results Webcast March 16, 2021 at 8:00 AM EDT 31st Annual Oppenheimer Healthcare Conference March 16, 2021 at 8:00 AM EDT 31st Annual Oppenheimer Healthcare Conference March 15, 2021 at 10:00 AM EDT 33rd Annual Roth Conference Webcast Link March 15, 2021 at 10:00 AM EDT 33rd Annual Roth Conference March 9, 2021 at 7:00 AM EST H.C Wainwright Global Life Sciences Conference November 24, 2020 at 4:00 PM IST Extraordinary General Meeting of shareholders of Vascular Biogenics Ltd. First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
June 4 - June 8, 2021 VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on 4-8 June 2021.
March 25, 2021 at 8:30 AM EDT VBL Therapeutics Fourth Quarter 2020 and Full Year Financial Results Webcast
November 24, 2020 at 4:00 PM IST Extraordinary General Meeting of shareholders of Vascular Biogenics Ltd.